CNR1 and Down syndrome: This finding aligns with previous studies by Ozaita and coworkers, who found improvements in the symptomatology of mouse models of fragile X and Down syndromes upon CB1R blockade (Busquets-Garcia et al, 2013; Navarro-Romero et al, 2019).